Chimeric Restriction Enzymes: What Is Next? : Biological Chemistry

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR increased in 2014: 3.268
Rank 106 out of 289 in category Biochemistry & Molecular Biology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 1.596
Source Normalized Impact per Paper (SNIP) 2014: 0.845
Impact per Publication (IPP) 2014: 2.992

VolumeIssuePage

Issues

Chimeric Restriction Enzymes: What Is Next?

S. Chandrasegaran / J. Smith

Citation Information: Biological Chemistry. Volume 380, Issue 7-8, Pages 841–848, ISSN (Print) 1431-6730, DOI: 10.1515/BC.1999.103, June 2005

Publication History

Published Online:
2005-06-01

Abstract

Chimeric restriction enzymes are a novel class of engineered nucleases in which the non-specific DNA cleavage domain of FokI (a type IIS restriction endonuclease) is fused to other DNA-binding motifs. The latter include the three common eukaryotic DNA-binding motifs, namely the helix-turn-helix motif, the zinc finger motif and the basic helix-loop-helix protein containing a leucine zipper motif. Such chimeric nucleases have been shown to make specific cuts in vitro very close to the expected recognition sequences. The most important chimeric nucleases are those based on zinc finger DNA-binding proteins because of their modular structure. Recently, one such chimeric nuclease, Zif-QQR-FN was shown to find and cleave its target in vivo. This was tested by microinjection of DNA substrates and the enzyme into frog oocytes (Carroll et al., 1999). The injected enzyme made site-specific double-strand breaks in the targets even after assembly of the DNA into chromatin. In addition, this cleavage activated the target molecules for efficient homologous recombination. Since the recognition specificity of zinc fingers can be manipulated experimentally, chimeric nucleases could be engineered so as to target a specific site within a genome. The availability of such engineered chimeric restriction enzymes should make it feasible to do genome engineering, also commonly referred to as gene therapy.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
A. Pingoud, G. G. Wilson, and W. Wende
Nucleic Acids Research, 2014, Volume 42, Number 12, Page 7489
[3]
K. M. Vasquez, K. Marburger, Z. Intody, and J. H. Wilson
Proceedings of the National Academy of Sciences, 2001, Volume 98, Number 15, Page 8403
[4]
M. Moore, A. Klug, and Y. Choo
Proceedings of the National Academy of Sciences, 2001, Volume 98, Number 4, Page 1437
[5]
Philippe Ruminy, Céline Derambure, Srinivasan Chandrasegaran, and Jean-Philippe Salier
Journal of Molecular Biology, 2001, Volume 310, Number 3, Page 523
[6]
Birgit Dreier, David J Segal, and Carlos F Barbas
Journal of Molecular Biology, 2000, Volume 303, Number 4, Page 489
[7]
David A. Sorrell and Andreas F. Kolb
Biotechnology Advances, 2005, Volume 23, Number 7-8, Page 431
[8]
Frank Buchholz
Current Opinion in Biotechnology, 2009, Volume 20, Number 4, Page 383
[9]
Mala Mani, Jeff Smith, Karthikeyan Kandavelou, Jeremy M. Berg, and Srinivasan Chandrasegaran
Biochemical and Biophysical Research Communications, 2005, Volume 334, Number 4, Page 1191
[10]
Mala Mani, Karthikeyan Kandavelou, Fei Jamie Dy, Sundar Durai, and Srinivasan Chandrasegaran
Biochemical and Biophysical Research Communications, 2005, Volume 335, Number 2, Page 447
[11]
Nicoletta Corbi, Valentina Libri, Annalisa Onori, and Claudio Passananti
Biochemistry and Cell Biology, 2004, Volume 82, Number 4, Page 428
[12]
Austin Burt and Vassiliki Koufopanou
Current Opinion in Genetics & Development, 2004, Volume 14, Number 6, Page 609
[13]
Frédéric Cedrone, André Ménez, and Eric Quéméneur
Current Opinion in Structural Biology, 2000, Volume 10, Number 4, Page 405
[14]
Arunas Silanskas, Michael Foss, Wolfgang Wende, Claus Urbanke, Arunas Lagunavicius, Alfred Pingoud, and Virginijus Siksnys
Biochemistry, 2011, Volume 50, Number 14, Page 2800
[15]
D Segal
Current Opinion in Chemical Biology, 2000, Volume 4, Number 1, Page 34
[16]
Seokjoong Kim and Jin-Soo Kim
Plant Biotechnology Reports, 2011, Volume 5, Number 1, Page 9
[17]
Götz Laible and Lucía Alonso-González
Biotechnology Journal, 2009, Volume 4, Number 9, Page 1278
[18]
Sarah Radecke, Frank Radecke, Toni Cathomen, and Klaus Schwarz
Molecular Therapy, 2010, Volume 18, Number 4, Page 743
[19]
Pei-Qi Liu, Edmond M. Chan, Gregory J. Cost, Lin Zhang, Jianbin Wang, Jeffrey C. Miller, Dmitry Y. Guschin, Andreas Reik, Michael C. Holmes, John E. Mott, Trevor N. Collingwood, and Philip D. Gregory
Biotechnology and Bioengineering, 2010, Page n/a
[20]
Miroslava Slaninová, Dominika Hroššová, Daniel Vlček, and Wolfgang Mages
Biologia, 2008, Volume 63, Number 6
[21]
Shondra M Pruett-Miller, Jon P Connelly, Morgan L Maeder, J Keith Joung, and Matthew H Porteus
Molecular Therapy, 2008, Volume 16, Number 4, Page 707
[22]
Matthew H Porteus and Dana Carroll
Nature Biotechnology, 2005, Volume 23, Number 8, Page 967
[23]
Yaakov Benenson, Tamar Paz-Elizur, Rivka Adar, Ehud Keinan, Zvi Livneh, and Ehud Shapiro
Nature, 2001, Volume 414, Number 6862, Page 430

Comments (0)

Please log in or register to comment.